First Ever Biosimilar Approval in China: Trouble for Roche?
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
CR Pharmaceutical Group Limited was set up in response to the requirement of the State-Owned Assets Supervision and Administration Commission of the State Council (SASAC) to “create a state-owned pharmaceutical platform” in 2007. It is an integrated enterprise group combining pharmaceutical R&D, manufacturing and production, as well as marketing under one umbrella. Leveraging its strong industrial base leading competitive advantages, CR Pharma is striving to “become the leader in China’s pharmaceutical industry”. In 2013, both turnover and assets of the company exceeded HK$100 billion, and CR Pharma ranked second in terms of overall strength in China’s pharmaceutical industry. On October 28, 2016, China Resources Pharmaceutical Group Limited (3320HK) was officially listed on the Hong Kong Stock Exchange.
CR Pharma owns two grade-1 profit centers, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., as well as famous companies including Shandong Dong-E-E-Jiao Pharmaceutical Co., Ltd., China Resources Zizhu Pharmaceutical Co., Ltd., China Resources Saike Pharmaceutical Co., Ltd., China Anhui World-Best Pharmaceutical Co., Ltd., and China Resources Pien Tze Huang Pharmaceutical Co., Ltd. Among them, CR Sanjiu (000999), CR Double-Crane, and Dong-E-E-Jiao (000423) are A-share pharmaceutical companies listed in China.
In the area of pharmaceutical manufacturing, CR Pharma is involved in natural medicine, Chinese medicine, chemical drugs, biological drugs and nutritional supplements. It ranked number one in the 2011 China Top 100 Pharmaceutical Manufacturing Enterprises, and owns well-known brands including “999”, “Double-Crane”, “Saike”, “Dong-E”, “Zizhu”, and “Yu Ting”.
In terms of retail and distribution, its business covers wholesale distribution of drugs, medical equipment, healthcare products, logistics, distribution, retail and supply chain value-added services. It ranks second among China’s pharmaceutical businesses and is the market leader in the areas of hospital drugs distribution and extended services, and modern logistics and distribution services in China.
CR Pharma possesses abundant and quality R&D resources, and strong independent innovation capabilities. It has established two national research centres for Chinese patent medicine and traditional Chinese gelatine medicine (Ejiao series), and numerous provincial level technology centres, serving as the R&D base for birth control and genital health drugs. It is leading the industry in pharmaceutical preparation and new pharmaceutical controlled-release technologies within China and is world-leading in its core R&D technology in pharmaceutical nucleoside intermediates. Through innovation and collaboration, CR Pharma will continue to focus on providing high-quality and reliable products and services to the public and will strive to become the market leader in China’s pharmaceutical industry.
China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats…
The lowdown on what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Robert Hall of Ardent Search outlines…
George Lee, vice-president of clinical operations and country leader of PAREXEL in China, discusses the impact of the recent ownership and management changes of the group, the value that PAREXEL…
One of the earliest innovative biotech companies in China, Zensun has developed what its founder Dr Zhou Mingdong calls a rare made-in-China first-in-class therapeutic candidate, the cardiology treatment, Neucardin®. With…
It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four…
This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging…
Terns Pharmaceuticals is developing innovative drugs for the treatment of NASH and liver disease. It has established a diverse product pipeline with drug candidates targeting different stages of the disease…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the…
Brian Mi, president of IQVIA Greater China, shares IQVIA’s leadership position in China in both the commercial and R&D space, building on both IMS Health and Quintiles’ market positioning in…
Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved…
Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein…
Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative…
See our Cookie Privacy Policy Here
